Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
ABEO filed a Form 144 reporting a proposed sale of Common Stock through Stifel Nicolaus on Nasdaq, dated 05/15/2026. The filing lists Restricted Stock Awards issued 08/13/2025 (6,326 shares) and 01/31/2026 (19,817 shares) that appear related to equity compensation.
Abeona Therapeutics reported its first meaningful commercial quarter for ZEVASKYN, generating $8.7 million in product revenue for the three months ended March 31, 2026. This compares to no revenue in the same period of 2025.
The company posted a net loss of $17.1 million, versus a $12.0 million loss a year earlier, as selling, general and administrative expenses rose to $19.5 million and research and development held roughly flat at $9.6 million. Loss from operations was $23.0 million.
Cash and cash equivalents were $61.4 million and short-term investments were $106.9 million, supporting total assets of $198.5 million and stockholders’ equity of $144.9 million. Management concluded existing capital resources are sufficient to fund operations for at least 12 months.
During the quarter Abeona signed a new license and joint development agreement with Reverence Enterprises for PSMA SIR-T T-cell therapy for prostate cancer, paying a $7.0 million upfront fee that was expensed as research and development. Warrant liabilities declined to $13.5 million as their fair value decreased.
Abeona Therapeutics reported first-quarter 2026 results highlighted by early ZEVASKYN commercialization and a new T‑cell therapy license. Net product revenue reached $8.7 million, a $6.3 million increase over the fourth quarter of 2025, driven by three ZEVASKYN patient treatments in the quarter.
Cost of sales was $2.7 million, while R&D totaled $9.6 million, including a $7.0 million upfront payment to in‑license PSMA‑SIR‑T, now ABO‑701. Selling, general and administrative expenses rose to $19.5 million as the company scaled commercial operations.
Abeona reported a net loss of $17.1 million, or $0.30 per share, compared with a $12.0 million loss a year earlier. Cash, cash equivalents and short‑term investments were $168.3 million as of March 31, 2026. The ZEVASKYN qualified treatment center network expanded to six sites, coverage policies now reach 95% of commercially insured U.S. lives, and the company plans to file an IND and begin first‑in‑human studies for ABO‑701 in the second half of 2027 while deprioritizing in‑house ophthalmology programs.
Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 5,548 shares of common stock at a weighted average price of $5.9613 per share. According to the filing, this sale was made specifically to cover tax obligations from the vesting of restricted stock awards, making it a mechanistic transaction rather than a discretionary portfolio change. Following the sale, Vasanthavada directly holds 313,071 shares of Abeona common stock, so the transaction represents a small portion of his overall reported holdings.
Abeona Therapeutics reports a 13G disclosure showing 3,100,000 shares of Common Stock beneficially owned, representing 5.4% of the class. The filing names AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman as reporting persons. The filing lists voting and dispositive power as sole for the full amount.
Abeona Therapeutics Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 12, 2026. Investors will elect three Class 1 directors for three-year terms, hold an advisory vote on executive pay, and ratify Deloitte & Touche LLP as auditor for 2026.
Stockholders are also asked to approve increasing shares reserved under the 2023 Equity Incentive Plan from 8,400,000 to 11,500,000 and to amend the Amended and Restated Certificate of Incorporation to remove the advance notice provision for director nominations. Each share of common stock outstanding as of April 15, 2026 has one vote.
Abeona Therapeutics Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held June 12, 2026 for routine corporate governance votes and several governance and compensation proposals. Key items include election of three Class 1 directors, an advisory say-on-pay vote, ratification of Deloitte & Touche LLP, approval to increase the 2023 Equity Incentive Plan reserve from 8,400,000 to 11,500,000 shares, and an amendment to remove the advance notice provision for director nominations.
The record date for voting is April 15, 2026; shares outstanding were 56,882,523 as of that date. The Board recommends FOR each nominee and each proposal noted above. Voting instructions, proxy-return methods, and virtual meeting access are provided in the proxy materials.
Goldan Keith A. reported acquisition or exercise transactions in this Form 4 filing.
Abeona Therapeutics Inc. director Keith A. Goldan received a grant of restricted common stock. He was awarded 32,751 shares of common stock at a stated price of $0.00 per share, increasing his directly held position to 32,751 shares after the transaction.
According to the filing, all of this restricted stock will vest on April 1, 2027, meaning the shares are subject to service-based conditions until that date and are compensation-related rather than an open-market purchase.